EAU 2018: Obese Patients Undergoing Robotic Radical Prostatectomy Have No Impaired Operative Outcome
Copenhagen, Denmark (UroToday.com) Outcome of obese patients after robotic assisted radical prostatectomy (RARP) is still controversially discussed. The authors evaluated the impact of obesity on operative- and perioperative outcome. In this study, obesity was defined as a Body Mass Index (BMI) of over 30.
EAU 2018: Is There an Age Limit for the Indication of Extended Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients with Clinically Localized Prostate Cancer?
Copenhagen, Denmark (UroToday.com) Available recommendations for extended lymph node dissection (eLND) at radical prostatectomy (RP) do not consider patient age, but rely on cancer characteristics only. However, for patients with limited life-expectancy, eLND might be an overtreatment. The authors hypothesized that limited life-expectancy of older RP candidates might dilute any beneficial effect of eLND in terms of cancer staging and outcomes. Therefore, the authors aimed to assess the differential effect of age on the risk of lymph node invasion (LNI) and mortality resulting from non-prostate cancer causes, to define an age limit above which eLND might be avoided.
EAU 2018: Does the Delay from Prostate Biopsy to Radical Prostatectomy Influence the Risk of Biochemical Recurrence?
Copenhagen, Denmark (UroToday.com) The influence of the delay between prostate biopsy (PB) and radical prostatectomy (RP) for patients with localized prostate cancer (PC) is controversial. The objective of this study was to establish a time limit between PB and RP beyond which the risks of upgrading and biochemical recurrence (BCR) are increased.
EAU 2018: What is the Learning Curve of Robot-Assisted Radical Prostatectomy in a Very High-Volume Open Radical Prostatectomy Center
Copenhagen, Denmark (UroToday.com) The goal of this study was to provide a comprehensive analysis of oncologic and functional outcomes, and complications of robotic assisted laparoscopic radical prostatectomies (RARP) performed by surgeons who have not performed RARP surgeries but have a history of high volume of open radical retropubic prostatectomies (RRP). The aim was to estimate the steepness of the learning curve of RARP among these surgeons.
EAU 2018: The Impact of Time from Diagnosis to Primary Radical Prostatectomy on Prostate Cancer-Specific Mortality
Copenhagen, Denmark (UroToday.com) Norway has a high incidence of prostate cancer (PCa). In 2016 approximately 5,100 Norwegian men were diagnosed with PCa. About 90% of them had local disease without distant metastases, and most of these patients were candidates for curative treatment, with a life expectancy of 10 years or more. To eliminate unnecessary delay in diagnosis and treatment, the Norwegian health authorities introduced in 2015 a fast-track system stating that patients eligible for primary radical prostatectomy (RP) should undergo surgery within 32 days of decision-making (“RP-interval”), irrespective of the risk group allocation.
EAU 2018: Prostate Radio-frequency Ablation Focal Treatment - ProRAFT
Copenhagen, Denmark (UroToday.com) Radiofrequency ablation (RFA) using a bipolar coil design (Encage® device) which acts as a Faraday cage offers the versatility needed to perform focal treatment of localised prostate cancer, whilst sparing critical anatomical and functional structures. In this study the authors report final outcomes of an ethics approved prospective development study, investigating focal Encage® ablation (NCT02294903). The primary objective was to determine the ablative efficacy 6 months after bipolar RFA against histology. The secondary objectives included the assessment of genito-urinary toxicity.
EAU 2018: Bi-parametric Prebiopsy MRI in Men with Clinical Suspicion of Prostate Cancer: Prospective Multi-center Validation Trial
Dr. Syvanen and colleagues from Finland presented results of their prospective multi-center validation trial of bi-parametric pre-biopsy MRI in men with clinical suspicion of prostate cancer at today’s EAU 2018 annual meeting. Over the past decade, MRI is widely used in the diagnostics and treatment planning of prostate cancer, but its role in a pre-biopsy setting is still controversial. The aim of the current study was to validate previous single center bi-parametric pre-biopsy MRI results in a prospective multi-centre trial.